Further assays demonstrated that engagement of the TCR by the specific causative drug and the treatment of a biomarker of SJS/TEN, IL-15 in vitro led to the downregulation of LEF-1 and TCF-1 expression in CD8+ T cells from SJS/TEN patients. This evidence concerns the gene CD8A and Schwartz-Jampel syndrome.